Design, synthesis and in-vivo hypoglycemic evaluation of novel non - TZD'S in a type - 2 diabetic model.
With a view to develop novel non-TZD anti-diabetic compounds, series of isoxazolidinediones were designed to target the PPAR-gamma receptors. Docking studies were performed on co-crystallized protein structure of rosiglitazone with PPAR-gamma receptor obt.....